Ruxolitinib waa molecule yar oo Janus kinase inhibitor ah oo loo isticmaalo daawaynta dhexe ama khatarta sare ee myelofibrosis iyo qaababka u adkaysta ee polycythemia vera iyo graft-vs-host disease.Ruxolitinib waxay la xiriirtaa ku-meel-gaar ah oo caadi ahaan sare u kaca ah ee serum aminotransferase inta lagu jiro daawaynta iyo marar dhif ah oo is-xaddidan, caafimaad ahaan u muuqda dhaawac beerka ba'an oo idiosyncratic ah iyo sidoo kale kiisaska dib-u-kicinta cagaarshowga B ee shakhsiyaadka u nugul.

Ruxolitinib waa daawada afka laga heli karo ee Janus-associated kinase (JAK) inhibitor ah oo leh waxqabadyo antineoplastic iyo immunomodulating suurtagal ah.Ruxolitinib wuxuu si gaar ah ugu xidhaa oo uu joojiyaa borotiinkatyrosinekinase JAK 1 iyo 2, taas oo keeni karta hoos u dhac ku yimaada bararka iyo xakameynta faafinta gacanta.Dariiqa JAK-STAT (calaamadaha calaamadeeyaha iyo dhaqdhaqaaqa qoraalka qoraalka) waxay door muhiim ah ka ciyaaraan calaamadaynta cytokines iyo arrimo badan oo korriin waxayna ku lug leeyihiin faafinta unugyada, koritaanka, hematopoiesis, iyo jawaabta difaaca;JAK kinase waxaa laga yaabaa in lagu hagaajiyo cudurrada bararka, xanuunka myeloproliferative, iyo malignancies kala duwan.

Ruxolitinib waa apyrazoleWaxaa lagu beddelay booska 1 koox 2-cyano-1-cyclopentyethyl ah iyo booska 3 koox pyrrolo [2,3-d] pyrimidin-4-yl ah.Waxaa loo isticmaalaa sida cusbada fosfatka ah ee loogu talagalay daaweynta bukaanada qaba myelofibrosis dhexdhexaad ah ama khatar sare leh, oo ay ku jiraan myelofibrosis aasaasiga ah, post-polycythemia vera myelofibrosis iyo post-esential thrombocythemia myelofibrosis.Waxay leedahay door sida wakiilka antineoplastic iyo EC 2.7.10.2 (protein aan gaar ahayn-tyrosinekinase) ka hortag.Waa nitrile, apyrrolopyrimidineiyo xubin ka mid ah pyrazoles.